TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02673866
Drug: DS-1971a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02673866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04203043
Drug: Pycnogenol Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
Study: NCT02179502
Drug: GLPG1690 single ascending doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
Study: NCT02179502
Drug: GLPG1690, multiple ascending doses, oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
Study: NCT04003792
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: systemic FOLFIRI chemotherapy
Study: NCT00744549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day with meals.
Study: NCT03062072
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
Study: NCT00069706
Drug: AL-12182 0.01% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT00069706
Drug: AL-12182 0.03% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT02764801
Drug: Ultrasound contrast agent (Contrast-enhanced ultrasound)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
Study: NCT01292694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, single administration, gelatin capsule filled with microcrystalline cellulose
Study: NCT00742508
Drug: SK&F-105517-D 10 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule once a day
Study: NCT00742508
Drug: SK&F-105517-D 20 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule once a day
Study: NCT00742508
Drug: SK&F-105517-D 40 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 capsule(s) once a day
Study: NCT02178306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-in phase
Study: NCT02046395
Drug: amlodipine, hydralazine, terazosin or hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
Study: NCT02648854
Drug: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
Study: NCT02648854
Drug: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
Study: NCT00003829
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03886779
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.7 MG/ML \[Prolensa\]
Study: NCT03886779
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 MG/ML \[Ilevro\]
Study: NCT00721279
Drug: Sifrol® (pramipexole dihydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02715505
Drug: Umbilical cord blood transplantation with HSC835
Normalized name: cow umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
Study: NCT00346047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding placebo is applied for 12weeks
Study: NCT00710684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to existing donepezil
Study: NCT02720263
Drug: ASP4345
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03429751
Drug: 30 ml/Kg/h crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Study: NCT03429751
Drug: 10 ml/Kg/h crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Study: NCT02338297
Drug: EGM
Normalized name: EGMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
Study: NCT03339726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of placebo capsule and tablet taken 4 hours apart
Study: NCT01092403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily by inhalation
Study: NCT02796859
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00983294
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
Study: NCT03558152
Drug: UTTR1147A
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
Study: NCT03558152
Drug: UTTR1147A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
Study: NCT02441270
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02730377
Drug: alpha-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study: NCT02730377
Drug: meglitinides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study: NCT02730377
Drug: sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study: NCT02730377
Drug: thiazolidinediones
Normalized name: Thiazolidinediones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study: NCT01715974
Drug: GM-CSF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
Study: NCT02111746
Drug: Patient Controlled Analgesia (PCA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
Study: NCT00438243
Drug: Bromfenac (Xibrom)
Normalized name: bromfenac Ophthalmic Solution [Xibrom]
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop to affected eye twice daily.
Study: NCT04401761
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 - 100 mg once daily at the discretion of the investigator
Study: NCT02643862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00006825
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04772846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets
Study: NCT00758459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing to match AZD1236
Study: NCT01572025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)
Study: NCT00961025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03384784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
Study: NCT03113123
Drug: PrEP with Truvada®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites.
Study: NCT01849068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks
Study: NCT01291537
Drug: best médical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00617695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01908465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01306318
Drug: eperisone hydrochloride plus diclofenac sodium capsule
Normalized name: diclofenac sodium Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
Study: NCT01306318
Drug: eperisone hydrochloride tablet and diclofenac sodium tablet
Normalized name: diclofenac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
Study: NCT01532336
Drug: NVC-422 Solution, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVC-422 Ophthalmic Solution dropped onto the eye
Study: NCT01532336
Drug: NVC-422 Vehicle Solution
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
Study: NCT00585013
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Study: NCT00922467
Drug: NaCl 9/00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume as in the esmolol group
Study: NCT01928342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule without coenzyme A.
Study: NCT00963924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
Study: NCT00524069
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03586674
Drug: Ursogal
Normalized name: Ursogal
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension
Study: NCT00545961
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixture, 0.28125 ml/kg twice a day for 7 days
Study: NCT02807428
Drug: AYX1 Injection 660 mg/6 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
Study: NCT02807428
Drug: Placebo Injection 6 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study: NCT01413789
Drug: Dermatix
Normalized name: Dermatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application of Dermatix
Study: NCT01413789
Drug: Kelocote
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application of Kelocote
Study: NCT00717314
Drug: CNI (≥75%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥75% reduction from BL
Study: NCT01413789
Drug: Alhydran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application of Alhydran
Study: NCT01413789
Drug: Bap Scar Care T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application of BAP Scar Care T
Study: NCT01413789
Drug: Bap Scar Care S
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Application of Bap Scar Care S
Study: NCT01413789
Drug: Mepiform
Normalized name: DRESSING,MEPIFORM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application of Mepiform
Study: NCT01413789
Drug: Scar Ban Elastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application of Scar Ban Elastic
Study: NCT00661206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in this group will receive placebo for 6 months.
Study: NCT03788226
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
Study: NCT00836537
Drug: Lotensin® 40 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 40 mg, single-dose fed
Study: NCT03845881
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Study: NCT01506765
Drug: N-Acetyl-Cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
Study: NCT02071862
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 monotherapy
Study: NCT02071862
Drug: Pac-CB
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 in combination with standard dose paclitaxel
Study: NCT02071862
Drug: CB-Erl
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 in combination with standard dose erlotnib
Study: NCT02071862
Drug: CB-Cabo
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 in combination with standard dose cabozantinib
Study: NCT00765895
Drug: Placebo (for nortriptyline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
Study: NCT00263328
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 5 mg BID
Study: NCT01910194
Drug: Luyxumia versus Lantus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00734682
Drug: Nanoliposomal CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
Study: NCT02833948
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)
Study: NCT02661958
Drug: S6G5T-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day topical cream
Study: NCT02661958
Drug: S6G5T-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day topical cream
Study: NCT02661958
Drug: S6G5T-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day topical cream
Study: NCT04044222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02661958
Drug: S6G5T-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day topical cream
Study: NCT00970632
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet po QD for 12 weeks
Study: NCT00970632
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule po QD for 12 weeks
Study: NCT01930188
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
Study: NCT01930188
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Study: NCT04685395
Drug: Ribamipide gargle \benzdymine HCL gargel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ribamipide gargle 6 time daily 5ml dosage
Study: NCT01327014
Drug: XueZhiKang (XZK), a botanic product with multiple components
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of study drug twice a day for 12 weeks.
Study: NCT01327014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules twice a day for 12 weeks.
Study: NCT03780465
Drug: NOX66 (A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idronoxil formulated in suppository base A
Study: NCT03780465
Drug: NOX66 (B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idronoxil formulated in suppository base B
Study: NCT01624857
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
Study: NCT01624857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
Study: NCT02027662
Drug: Osvaren Granules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02027662
Drug: Osvaren film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02588716
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
Study: NCT02848482
Drug: Irrigation
Normalized name: Eye Irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
Study: NCT00736489
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, single dose
Study: NCT00736489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, single dose
Study: NCT02450084
Drug: IV-PCA containing Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
Study: NCT01921192
Drug: Folic Acid, vit B6 and B12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00482911
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25-50 mg by mouth once daily on days 1-28.
Study: NCT00257894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules containing inert filler taken orally for a total of 12 days
Study: NCT01921192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01898221
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
Study: NCT04182854
Drug: Furosemid hydrochlorothiazide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
Study: NCT00855010
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one daily
Study: NCT01435096
Drug: BN80927
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
Study: NCT00921102
Drug: Isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine
Study: NCT03024684
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet daily